Literature DB >> 942500

Clinical studies of antibodies binding polyriboadenylic acid in systemic lupus erythematosus.

R J Pillarisetty, N Talal.   

Abstract

Antibodies of polyriboadenylic acid (poly rA) are demonstrated by filter radioimmunoassay in 75% of patients with systemic lupus erythematosus (SLE), in 54% of patients with discoid lupus erythematosus, and in only 0-7% of normal controls and patients with rheumatoid arthritis or Sjögren's syndrome. These antibodies are distinct from antibodies to single- and double-stranded DNA and double-stranded RNA. Poly rA binding is associated with IgM and IgG serum fractions. Because poly rA may have a role in the transcription of mRNA in mammalian cells and viruses, antibodies to poly rA may be important clues to virologic and immunogenetic mechanisms in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 942500     DOI: 10.1002/1529-0131(197607/08)19:4<705::aid-art1780190408>3.0.co;2-k

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

1.  Monoclonal anti-poly(rA) hybridoma antibodies from an autoimmune MRL/MpJ-lpr/lpr mouse.

Authors:  H Dang; M Fischbach; M Erdos; N Talal
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

2.  Antibodies against nuclear poly(A) polymerases in rheumatic autoimmune diseases.

Authors:  D A Stetler; M Reichlin; C M Berlin; S T Jacob
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

Review 3.  Systemic diseases and the detection of antinuclear and anticytoplasmic antibodies. An historical review.

Authors:  M Walravens
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

4.  Genetic analysis of induction of anti-polyadenylic acid antibodies and xenotropic type-C viruses.

Authors:  M Fischbach; P Volberding; N Talal; J Levy
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

5.  Antibodies to polyadenylic acid in patients with myasthenia gravis.

Authors:  M Fischbach; J Lindstrom; N Talal
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.